Levobunolol

Summary

Levobunolol (CHEMBL1201237) is an approved small-molecule antiglaucoma drug (ATC S01ED03); indicated across 1 condition including glaucoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: S01ED03
• Indications: 1 condition
• Chemistry: 291.4 Da · C17H25NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201237
Name	Levobunolol
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	39468
ChEBI	CHEBI:6438
ATC	S01ED03
Molecular formula	C17H25NO3
Molecular weight	291.4
InChIKey	IXHBTMCLRNMKHZ-LBPRGKRZSA-N

SMILES: CC(C)(C)NC[C@@H](COC1=CC=CC2=C1CCCC2=O)O

IUPAC name: 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-2H-naphthalen-1-one

ChEBI definition: A cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective β-adrenergic antagonist used (as its hydrochloride salt) for treatment of glaucoma.

Pharmacological roles (ChEBI): antiglaucoma drug, β-adrenergic antagonist.

Also known as: Bunolol, (-)-, Bunolol, (s)-, Levobunolol, SID11112713, SID11112712, levobunolol, LEVOBUNOLOL

Parent form; salt/anhydrous children: CHEMBL1201177

Patent coverage: 2,625 distinct patent families (10,597 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: 4’-phosphopantetheinyl transferase ffp, Thyrotropin receptor, Beta-2 adrenergic receptor, Beta-1 adrenergic receptor, 5-hydroxytryptamine receptor 1A, Sodium-dependent serotonin transporter, Beta-3 adrenergic receptor, 5-hydroxytryptamine receptor 1A, Sigma non-opioid intracellular receptor 1.

Bioactivity

ChEMBL activities: 15 potent at pChembl ≥ 5 of 16 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ADRB2	9.26	Ki	0.55	nM	CHEMBL_ACT_7750841
ADRB2	9.1	IC50	0.79	nM	CHEMBL_ACT_7750840
ADRB1	8.4	Ki	3.98	nM	CHEMBL_ACT_7750839
ADRB1	8.16	IC50	6.9	nM	CHEMBL_ACT_7750838
ADRB3	6.59	Ki	255	nM	CHEMBL_ACT_7750843
SIGMAR1	6.49	Ki	325	nM	CHEMBL_ACT_7753066
ADRB3	6.47	IC50	340	nM	CHEMBL_ACT_7750842
SIGMAR1	6.11	IC50	773	nM	CHEMBL_ACT_7753065
HTR1A	6.05	AC50	886	nM	CHEMBL_ACT_25165509
P19327	5.78	Ki	1658	nM	CHEMBL_ACT_7753048
SLC6A4	5.58	Ki	2602	nM	CHEMBL_ACT_7753064
P19327	5.54	IC50	2901	nM	CHEMBL_ACT_7753047
SLC6A4	5.31	IC50	4898	nM	CHEMBL_ACT_7753063
TSHR	5.1	Potency	7943	nM	CHEMBL_ACT_3915711
TSHR	5.1	Potency	7943	nM	CHEMBL_ACT_4751043

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
glaucoma	4	MONDO:0005041	MONDO:0005041

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).